# A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies

Source: https://onco.cc/trials/nct07609862/  
OnCo record `nct07609862` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Rocbrutinib in mantle cell lymphoma and diffuse large b-cell lymphoma, run by Guangzhou Lupeng Pharmaceutical Company LTD., now recruiting.

## Summary

A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies is a phase 1/2 interventional study registered as NCT07609862 by Guangzhou Lupeng Pharmaceutical Company LTD., with 92 participants planned, started 2026-07-14 and due to reach its primary completion in 2029-06-30. Interventions recorded: Lacutoclax+Rocbrutinib. Conditions listed: Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström Macroglobulinemia (WM). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07609862
- Phase: 1/2
- Setting: A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTK Inhibitor Rocbrutinib in Combination With BCL-2 Inhibitor Lacutoclax in Patients With B-Cell Malignancies
- Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.
- Enrolled: 92

## Sources

- ClinicalTrials.gov NCT07609862: https://clinicaltrials.gov/study/NCT07609862

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- drugs: [Rocbrutinib](https://onco.cc/drugs/rocbrutinib/)

---
JSON: https://onco.cc/api/v1/entities/nct07609862.json